• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对伴有动脉毗邻的胰腺腺癌, upfront手术与新辅助放化疗后手术的治疗权重逆概率分析

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.

作者信息

Fujii Tsutomu, Yamada Suguru, Murotani Kenta, Kanda Mitsuro, Sugimoto Hiroyuki, Nakao Akimasa, Kodera Yasuhiro

机构信息

From the Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine (TF, SY, MK, HS, AN, YK), and Center for Clinical Research, Aichi Medical University, Nagakute, Japan (KM).

出版信息

Medicine (Baltimore). 2015 Sep;94(39):e1647. doi: 10.1097/MD.0000000000001647.

DOI:10.1097/MD.0000000000001647
PMID:26426657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4616842/
Abstract

Combined arterial resection during pancreatectomy can be a challenging treatment, and outcome would be more favorable if the tumor becomes technically removable from the artery. Neoadjuvant chemoradiotherapy (NACRT) is expected to achieve locoregional control and enable margin-negative resection. To investigate the effects of NACRT in patients with pancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA), but were still considered to be technically removable. In the current study, comparisons were make between 71 patients who underwent upfront surgery and 21 patients who underwent NACRT followed by surgery in the strategy to preserve the artery, using unmatched and inverse probability of treatment weighting analysis (UMIN000017115). Fifty patients in the upfront surgery group and 18 in the NACRT group underwent curative resection (70% vs 86%, respectively; P = 0.16). The results of the propensity score weighted logistic regressions indicated that the incidences of pathological lymph node metastasis and a pathological positive resection margin were significantly lower in the NACRT group (odds ratio, 0.006; P < 0.001 and odds ratio, 0.007; P < 0.001, respectively). Among the propensity-score matched patients, the estimated 1- and 2-year survival rates in the upfront surgery group were 66.7% and 16.0%, respectively, and those in the NACRT group were 80.0% and 65.2%, respectively. In conclusion, it was suggested that chemoradiotherapy followed by surgery provided clinical benefits in patients with PDACs in contact with the SMA or CHA.

摘要

胰腺切除术中联合动脉切除可能是一项具有挑战性的治疗方法,如果肿瘤在技术上能够从动脉上切除,预后可能会更好。新辅助放化疗(NACRT)有望实现局部区域控制并实现切缘阴性切除。本研究旨在探讨NACRT对因肠系膜上动脉(SMA)或肝总动脉(CHA)等主要动脉毗邻而在术前影像学检查中被判定为边界可切除但仍被认为在技术上可切除的胰腺腺癌(PDAC)患者的影响。在本研究中,采用非匹配和治疗权重逆概率分析(UMIN000017115),对71例接受直接手术的患者和21例接受NACRT后再手术以保留动脉的患者进行了比较。直接手术组的50例患者和NACRT组的18例患者接受了根治性切除(分别为70%和86%;P = 0.16)。倾向评分加权逻辑回归结果表明,NACRT组病理淋巴结转移和病理切缘阳性的发生率显著较低(优势比分别为0.006;P < 0.001和优势比为0.007;P < 0.001)。在倾向评分匹配的患者中,直接手术组的1年和2年估计生存率分别为66.7%和16.0%,NACRT组分别为80.0%和65.2%。总之,研究表明,先进行放化疗再手术对与SMA或CHA接触的PDAC患者具有临床益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/e2a2ee855764/medi-94-e1647-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/2da2e0a1ef62/medi-94-e1647-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/bb67153eab65/medi-94-e1647-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/e2a2ee855764/medi-94-e1647-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/2da2e0a1ef62/medi-94-e1647-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/bb67153eab65/medi-94-e1647-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2329/4616842/e2a2ee855764/medi-94-e1647-g007.jpg

相似文献

1
Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.针对伴有动脉毗邻的胰腺腺癌, upfront手术与新辅助放化疗后手术的治疗权重逆概率分析
Medicine (Baltimore). 2015 Sep;94(39):e1647. doi: 10.1097/MD.0000000000001647.
2
Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.新辅助放化疗治疗胰头腺癌的临床获益:一项使用逆概率治疗加权的观察性研究。
J Gastroenterol. 2017 Jan;52(1):81-93. doi: 10.1007/s00535-016-1217-x. Epub 2016 May 11.
3
Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.中性粒细胞与淋巴细胞比值对新辅助放化疗后手术切除的边界可切除胰腺导管腺癌的预后影响。
World J Surg. 2019 Dec;43(12):3153-3160. doi: 10.1007/s00268-019-05159-9.
4
Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.新辅助化疗和放化疗对边界可切除胰腺癌的临床影响:884 例胰腺外科专科医院患者的分析。
Ann Surg Oncol. 2019 Jun;26(6):1629-1636. doi: 10.1245/s10434-018-07131-8. Epub 2019 Jan 4.
5
Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.覆膜自膨式金属支架置入术有望使边界可切除胰头癌患者安全接受新辅助放化疗。
Dig Endosc. 2014 Jan;26(1):77-86. doi: 10.1111/den.12049. Epub 2013 Mar 31.
6
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.新辅助放化疗对局部可切除胰腺导管腺癌患者的免疫影响。
Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.
7
Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.新辅助放化疗后可切除胰腺癌患者行胰腺切除术的肿瘤位置、临床病理特征及围手术期和预后结果:一项回顾性研究。
Pancreatology. 2024 May;24(3):431-436. doi: 10.1016/j.pan.2024.02.007. Epub 2024 Feb 16.
8
Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.局部晚期胰腺癌新辅助放化疗后肠系膜上动脉神经丛的最佳切除范围
Medicine (Baltimore). 2018 Aug;97(31):e11309. doi: 10.1097/MD.0000000000011309.
9
Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.新辅助放化疗后手术治疗的胰腺癌患者术后胰瘘降低其生存率:一项回顾性分析。
Surg Oncol. 2020 Dec;35:527-532. doi: 10.1016/j.suronc.2020.10.010. Epub 2020 Oct 24.
10
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.网络荟萃分析比较新辅助放化疗、新辅助化疗和直接手术治疗可切除、交界可切除和局部进展期胰腺导管腺癌患者的疗效。
Radiat Oncol. 2019 Jul 10;14(1):120. doi: 10.1186/s13014-019-1330-0.

引用本文的文献

1
Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis.可切除和交界可切除胰腺癌的 upfront 手术与新辅助治疗比较:一项更新的系统评价和荟萃分析。
Updates Surg. 2024 Jan;76(1):1-15. doi: 10.1007/s13304-023-01626-0. Epub 2023 Aug 28.
2
Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study.80 岁以上胰头十二指肠切除术治疗胰管腺癌的肿瘤学结果:病例对照研究。
BJS Open. 2023 Jul 10;7(4). doi: 10.1093/bjsopen/zrad053.
3
Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer.

本文引用的文献

1
Excess Weight Adversely Influences Treatment Length of Postoperative Pancreatic Fistula: A Retrospective Study of 900 Patients.超重对术后胰瘘治疗时长产生不利影响:一项对900例患者的回顾性研究
Pancreas. 2015 Aug;44(6):971-6. doi: 10.1097/MPA.0000000000000352.
2
The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.放射治疗在新辅助和辅助治疗环境下对胰腺导管腺癌的作用。
Semin Oncol. 2015 Feb;42(1):144-62. doi: 10.1053/j.seminoncol.2014.12.013. Epub 2014 Dec 8.
3
Vein resections >3 cm during pancreatectomy are associated with poor 1-year patency rates.
可切除或临界可切除胰腺癌围手术期治疗的当前价值
Yonago Acta Med. 2023 May 10;66(2):202-207. doi: 10.33160/yam.2023.05.014. eCollection 2023 May.
4
Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.可切除和交界可切除胰腺导管腺癌的新辅助和辅助治疗:日本胰腺导管腺癌治疗的现状。
Gut Liver. 2023 Sep 15;17(5):698-710. doi: 10.5009/gnl220311. Epub 2023 Feb 27.
5
Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience.基于可切除性的胰腺癌预后:单中心经验
Cancers (Basel). 2023 Feb 9;15(4):1101. doi: 10.3390/cancers15041101.
6
Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy.Rubicon可预测新辅助放化疗后胰腺导管腺癌患者的预后。
Int J Clin Oncol. 2023 Apr;28(4):576-586. doi: 10.1007/s10147-023-02306-0. Epub 2023 Feb 24.
7
Hepatic artery resection in distal cholangiocarcinoma.肝动脉切除在远端胆管癌中的应用。
Langenbecks Arch Surg. 2023 Jan 23;408(1):58. doi: 10.1007/s00423-022-02749-5.
8
Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study.S-1剂量降低的辅助化疗对胰腺癌患者的治疗效果:一项回顾性研究
BMC Cancer. 2022 Sep 30;22(1):1028. doi: 10.1186/s12885-022-10116-2.
9
Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties.局部晚期胰腺癌切缘状态的病理报告:挑战与不确定性
J Gastrointest Oncol. 2021 Oct;12(5):2512-2520. doi: 10.21037/jgo-20-391.
10
Pancreatic Cancer: "Whether to Cross the Border"?胰腺癌:“是否跨越边界”?
Indian J Surg Oncol. 2021 Jun;12(2):235-237. doi: 10.1007/s13193-021-01341-5. Epub 2021 May 8.
胰腺切除术中静脉切除长度>3 cm与1年通畅率低相关。
Surgery. 2015 Apr;157(4):708-15. doi: 10.1016/j.surg.2014.12.002. Epub 2015 Feb 20.
4
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.FOLFIRINOX新辅助治疗对局部晚期和边界可切除胰腺癌的放射学及外科意义
Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.
5
Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.新辅助FOLFIRINOX方案应用于可切除边缘的胰腺腺癌:一项回顾性队列研究。
Medicine (Baltimore). 2014 Dec;93(27):e198. doi: 10.1097/MD.0000000000000198.
6
Preoperative internal biliary drainage increases the risk of bile juice infection and pancreatic fistula after pancreatoduodenectomy: a prospective observational study.术前内镜下胆道引流增加胰十二指肠切除术后胆汁感染和胰瘘风险:一项前瞻性观察研究
Pancreas. 2015 Apr;44(3):465-70. doi: 10.1097/MPA.0000000000000265.
7
Arterial resection at the time of pancreatectomy for cancer.胰腺癌胰十二指肠切除术中的动脉切除
Surgery. 2014 May;155(5):919-26. doi: 10.1016/j.surg.2014.01.003. Epub 2014 Jan 22.
8
Modified Blumgart anastomosis for pancreaticojejunostomy: technical improvement in matched historical control study.改良 Blumgart 吻合术在胰肠吻合术中的应用:匹配历史对照研究中的技术改进。
J Gastrointest Surg. 2014 Jun;18(6):1108-15. doi: 10.1007/s11605-014-2523-3. Epub 2014 Apr 15.
9
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.新辅助放化疗对局部可切除胰腺导管腺癌患者的免疫影响。
Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.
10
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.吉西他滨辅助化疗与可切除胰腺癌患者长期结局:CONKO-001 随机试验。
JAMA. 2013 Oct 9;310(14):1473-81. doi: 10.1001/jama.2013.279201.